中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2010年
3期
234-236
,共3页
吴芳%陈述嫦%卢致辉%熊建萍
吳芳%陳述嫦%盧緻輝%熊建萍
오방%진술항%로치휘%웅건평
胃肿瘤%紫杉醇脂质体%紫杉醇%氟尿嘧啶%联合化疗
胃腫瘤%紫杉醇脂質體%紫杉醇%氟尿嘧啶%聯閤化療
위종류%자삼순지질체%자삼순%불뇨밀정%연합화료
Stomach neoplasms%Paclitaxel liposome%Paclitaxel%Fluorouracil%Combined chemotherapy
目的 比较紫杉醇脂质体联合5-氟尿嘧啶(5-Fu)与紫杉醇联合5-Fu一线治疗晚期胃癌的近期疗效、不良反应及预后.方法 经病理或细胞学证实的67例晚期胃癌患者,31例接受紫杉醇脂质体联合5-Fu方案化疗(力扑素组),34例接受紫杉醇联合5-Fu方案化疗(紫杉醇组).按照世界卫生组织(WHO)标准评价近期疗效,按照WHO关于化疗药物不良反应的评价标准评价不良反应.结果 力扑素组和紫杉醇组的客观有效率分别为54.8%和44.1%(P=0.388),中位疾病进展时间分别为5.10和5.20个月(P=O.266),中位生存时间分别为10.07和8.97个月(P=0.186).力扑素组和紫杉醇组的主要不良反应为血液学毒性及恶心呕吐,Ⅲ～Ⅳ度恶心呕吐的发生率为16.1%和50.0%(P=0.038),肌肉关节痛的发生率为9.7%和29.4%(P=0.047).结论 紫杉醇脂质体联合5-Fu使用方便,与紫杉醇联合5-Fu一线治疗晚期胃癌疗效相当,但Ⅲ～Ⅳ度不良反应发生率较低.
目的 比較紫杉醇脂質體聯閤5-氟尿嘧啶(5-Fu)與紫杉醇聯閤5-Fu一線治療晚期胃癌的近期療效、不良反應及預後.方法 經病理或細胞學證實的67例晚期胃癌患者,31例接受紫杉醇脂質體聯閤5-Fu方案化療(力撲素組),34例接受紫杉醇聯閤5-Fu方案化療(紫杉醇組).按照世界衛生組織(WHO)標準評價近期療效,按照WHO關于化療藥物不良反應的評價標準評價不良反應.結果 力撲素組和紫杉醇組的客觀有效率分彆為54.8%和44.1%(P=0.388),中位疾病進展時間分彆為5.10和5.20箇月(P=O.266),中位生存時間分彆為10.07和8.97箇月(P=0.186).力撲素組和紫杉醇組的主要不良反應為血液學毒性及噁心嘔吐,Ⅲ～Ⅳ度噁心嘔吐的髮生率為16.1%和50.0%(P=0.038),肌肉關節痛的髮生率為9.7%和29.4%(P=0.047).結論 紫杉醇脂質體聯閤5-Fu使用方便,與紫杉醇聯閤5-Fu一線治療晚期胃癌療效相噹,但Ⅲ～Ⅳ度不良反應髮生率較低.
목적 비교자삼순지질체연합5-불뇨밀정(5-Fu)여자삼순연합5-Fu일선치료만기위암적근기료효、불량반응급예후.방법 경병리혹세포학증실적67례만기위암환자,31례접수자삼순지질체연합5-Fu방안화료(력복소조),34례접수자삼순연합5-Fu방안화료(자삼순조).안조세계위생조직(WHO)표준평개근기료효,안조WHO관우화료약물불량반응적평개표준평개불량반응.결과 력복소조화자삼순조적객관유효솔분별위54.8%화44.1%(P=0.388),중위질병진전시간분별위5.10화5.20개월(P=O.266),중위생존시간분별위10.07화8.97개월(P=0.186).력복소조화자삼순조적주요불량반응위혈액학독성급악심구토,Ⅲ～Ⅳ도악심구토적발생솔위16.1%화50.0%(P=0.038),기육관절통적발생솔위9.7%화29.4%(P=0.047).결론 자삼순지질체연합5-Fu사용방편,여자삼순연합5-Fu일선치료만기위암료효상당,단Ⅲ～Ⅳ도불량반응발생솔교저.
Objective To explore the efficacy,time to disease progression(TTP),overall survival (os)and toxicity of pachtaxel lipasome versus paclitaxel combined with 5-fluorouracil(5-Fu)for patients with advanced gastric cancer.Methods The therapeutic efficacy of chemotherapy with either of the tworegimens for 67 cases of na(i)ve advanced gastric cancer was analyzed. Among them,31 patients in the paclitaxel liposome-5-Fu group received paclitaxel liposome 175 mg/m~2 d1,CF 200 ms/m~2 d1,5-Fu 2.6 g/m~2civ.46 hours,21 days as one cycle,and 34 patients in the paclitaxel-5-Fu group received paclitaxel 175 mg/m~2 d1,CF200mg/m~2 d1,5-Fu 2.6 g/m~2 civ.46 hours,21 days as one cycle.Results The objective response ratewas 54.8% in the paclitaxel liposome group and 44.1%in the paclitaxel group(P=O.388).The median time to progression was 5.10 months VS.5.20 months(P=0.266)and the median survival time wan 10.07 months v8.8.97 months(P=0.186).The most frequent side-effects were nausea,vomit and hematological toxicities.The rates of gradeⅢ-Ⅳ nausea and vomit were 16.1%and 50.0%(P=0.038),muscle and joint pain were 9.7%and 29.4%(P=0.047).Conclusion Both regimens are effective in the treatment of advanced gastric cancer.However,less adverse effects occur in the paclitaxel liposome group.
